| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return | vs S&P 500 ⓘ |
|---|---|---|---|---|---|---|
|
STTK
Shattuck Labs
|
Aug 12, 2026 | BUY |
Strong Buy
+196.6% avg upside
15 analysts
|
$13.00
77.66% Upside
|
-0.9% | · |
|
PTGX
Protagonist Therapeutics
|
Aug 12, 2026 | BUY |
Strong Buy
-23.0% avg upside
19 analysts
|
$149.00
1.63% Downside
|
+2.0% | · |
|
GLUE
Monte Rosa Therapeutics
|
Aug 10, 2026 | BUY |
Strong Buy
+40.2% avg upside
15 analysts
|
$27.00
70.54% Upside
|
-2.0% | · |
|
ROIV
Roivant Sciences
|
Aug 10, 2026 | BUY |
Strong Buy
-2.0% avg upside
17 analysts
|
$40.00
10.31% Upside
|
+1.2% | · |
|
IMVT
Immunovant
|
Aug 10, 2026 | BUY |
Strong Buy
-4.2% avg upside
24 analysts
|
$50.00
19.53% Upside
|
+4.8% | · |
|
TGTX
TG Therapeutics
|
Aug 10, 2026 | BUY |
Strong Buy
-7.3% avg upside
20 analysts
|
$72.00
50.18% Upside
|
-0.9% | · |
|
ODTX
Odyssey Therapeutics, Inc.
|
Aug 10, 2026 | BUY |
Strong Buy
+59.3% avg upside
5 analysts
|
$29.00
39.90% Upside
|
-6.5% | · |
|
RVMD
Revolution Medicines
|
Aug 07, 2026 | BUY |
Strong Buy
-16.5% avg upside
32 analysts
|
$227.00
12.36% Upside
|
-0.7% | · |
|
ARWR
Arrowhead Pharmaceuticals
|
Aug 06, 2026 | BUY |
Strong Buy
-12.5% avg upside
27 analysts
|
$100.00
16.92% Upside
|
+1.7% | · |
|
KYMR
Kymera Therapeutics
|
Aug 06, 2026 | BUY |
Strong Buy
-7.7% avg upside
37 analysts
|
$121.00
5.71% Upside
|
+10.3% | · |
|
BEAM
Beam Therapeutics
|
Aug 06, 2026 | BUY |
Strong Buy
+96.3% avg upside
25 analysts
|
$44.00
66.06% Upside
|
-1.8% | · |
|
TNGX
Tango Therapeutics
|
Jul 15, 2026 | BUY |
Strong Buy
+53.0% avg upside
15 analysts
|
$46.00
79.28% Upside
|
-15.4% | · |
|
PTCT
PTC Therapeutics
|
Jul 13, 2026 | BUY |
Strong Buy
+12.5% avg upside
29 analysts
|
$91.00
26.51% Upside
|
-11.8% | · |
|
TARA
Protara Therapeutics
|
Jun 30, 2026 | BUY |
Strong Buy
+1211.6% avg upside
21 analysts
|
— | +3.9% | · |
|
IMNM
Immunome
|
Jun 29, 2026 | BUY |
Strong Buy
+27.7% avg upside
16 analysts
|
— | +29.3% | · |
|
EIKN
Eikon Therapeutics, Inc.
|
May 31, 2026 | BUY |
Buy
+129.9% avg upside
5 analysts
|
— | +2.4% | · |
|
KYTX
Kyverna Therapeutics, Inc.
|
May 13, 2026 | BUY |
Strong Buy
+238.1% avg upside
7 analysts
|
$29.00
258.86% Upside
|
-24.2% | · |
|
NTLA
Intellia Therapeutics
|
May 13, 2026 | SELL |
Buy
+226.5% avg upside
37 analysts
|
$8.00
32.39% Downside
|
+16.6% | · |
|
CGON
CG Oncology, Inc.
|
May 11, 2026 | BUY |
Strong Buy
+14.7% avg upside
17 analysts
|
$96.00
28.43% Upside
|
+8.2% | · |
|
XNCR
Xencor
|
May 11, 2026 | HOLD |
Strong Buy
+50.6% avg upside
27 analysts
|
$14.00
39.10% Downside
|
+82.5% | · |
|
ALLO
Allogene Therapeutics
|
Apr 16, 2026 | HOLD |
Strong Buy
+667.0% avg upside
28 analysts
|
— | -13.5% | · |
|
AAPG
Ascentage Pharma Group International Unsponsored ADR
|
Apr 15, 2026 | BUY |
Strong Buy
+143.9% avg upside
10 analysts
|
$46.00
142.16% Upside
|
-29.9% | · |
|
EDIT
Editas Medicine
|
Mar 13, 2026 | SELL |
Buy
+385.5% avg upside
33 analysts
|
— | -15.6% | · |
|
ZYME
Zymeworks
|
Mar 03, 2026 | BUY |
Strong Buy
+29.0% avg upside
25 analysts
|
— | +2.7% | · |
|
CRSP
Crispr Therapeutics AG
|
Feb 13, 2026 | BUY |
Buy
+40.1% avg upside
41 analysts
|
$67.00
24.16% Upside
|
+0.9% | · |
|
PLRX
Pliant Therapeutics
|
Dec 04, 2025 | SELL |
Buy
+1960.5% avg upside
21 analysts
|
— | +18.3% | · |
|
OPK
Opko Health
|
Nov 20, 2025 | HOLD |
Buy
+381.8% avg upside
12 analysts
|
— | +6.2% | · |
|
ABSI
AbSci
|
Oct 02, 2025 | BUY |
Strong Buy
+28.7% avg upside
18 analysts
|
— | +158.6% | · |
|
PGEN
Precigen
|
Aug 15, 2025 | HOLD |
Strong Buy
+286.3% avg upside
11 analysts
|
— | +107.5% | · |
|
ADCT
ADC Therapeutics
|
Mar 21, 2025 | HOLD |
Buy
+472.1% avg upside
12 analysts
|
— | +139.8% | · |
|
BCAB
BioAtla
|
Sep 13, 2024 | HOLD |
Strong Buy
+2676.4% avg upside
13 analysts
|
— | · | · |
|
CHRS
Coherus Biosciences
|
Jul 15, 2024 | HOLD |
Buy
+985.1% avg upside
18 analysts
|
— | -48.5% | · |
|
MGX
Metagenomi, Inc.
|
May 02, 2024 | HOLD |
Strong Buy
+589.9% avg upside
8 analysts
|
$6.00
387.77% Upside
|
-73.9% | · |
|
ACET
Adicet Bio
|
Jun 01, 2023 | HOLD |
Strong Buy
+205.8% avg upside
14 analysts
|
$6.00
27.35% Downside
|
-72.1% | · |
|
SNTI
Senti Biosciences
|
Dec 16, 2022 | HOLD |
Strong Buy
+2196.3% avg upside
7 analysts
|
— | -75.0% | · |
|
GOSS
Gossamer Bio
|
Dec 07, 2022 | SELL |
Buy
+3894.2% avg upside
17 analysts
|
— | +50.0% | · |
|
PRQR
ProQR
|
Apr 19, 2022 | BUY |
Strong Buy
+509.8% avg upside
18 analysts
|
$3.50
89.11% Upside
|
+193.4% | · |
|
BCRX
BioCryst
|
Apr 08, 2022 | BUY |
Strong Buy
+84.4% avg upside
24 analysts
|
$17.00
73.21% Upside
|
-21.9% | · |
|
LUCD
Lucid Diagnostics
|
Apr 04, 2022 | BUY |
Strong Buy
+400.4% avg upside
8 analysts
|
$12.00
1143.57% Upside
|
-62.2% | · |
|
ARCT
Arcturus Therapeutics
|
Mar 01, 2022 | BUY |
Buy
+274.0% avg upside
36 analysts
|
$86.00
994.09% Upside
|
-26.2% | · |
|
EQ
Equillium
|
Nov 02, 2021 | BUY |
Strong Buy
+365.2% avg upside
16 analysts
|
$14.00
596.60% Upside
|
-73.3% | · |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.